Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.66
LGND's Cash-to-Debt is ranked lower than
82% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. LGND: 0.66 )
Ranked among companies with meaningful Cash-to-Debt only.
LGND' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18  Med: 0.65 Max: No Debt
Current: 0.66
Equity-to-Asset 0.57
LGND's Equity-to-Asset is ranked lower than
57% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. LGND: 0.57 )
Ranked among companies with meaningful Equity-to-Asset only.
LGND' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.49  Med: 0.05 Max: 0.57
Current: 0.57
-0.49
0.57
Interest Coverage 3.63
LGND's Interest Coverage is ranked lower than
93% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. LGND: 3.63 )
Ranked among companies with meaningful Interest Coverage only.
LGND' s Interest Coverage Range Over the Past 10 Years
Min: 0.06  Med: 5.62 Max: No Debt
Current: 3.63
Piotroski F-Score: 5
Altman Z-Score: 5.32
Beneish M-Score: -1.43
WACC vs ROIC
12.03%
1.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 40.27
LGND's Operating Margin % is ranked higher than
93% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. LGND: 40.27 )
Ranked among companies with meaningful Operating Margin % only.
LGND' s Operating Margin % Range Over the Past 10 Years
Min: -466.69  Med: -6.83 Max: 40.27
Current: 40.27
-466.69
40.27
Net Margin % -1.50
LGND's Net Margin % is ranked higher than
66% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. LGND: -1.50 )
Ranked among companies with meaningful Net Margin % only.
LGND' s Net Margin % Range Over the Past 10 Years
Min: -359.19  Med: 8.57 Max: 2184.64
Current: -1.5
-359.19
2184.64
ROE % -0.48
LGND's ROE % is ranked higher than
69% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. LGND: -0.48 )
Ranked among companies with meaningful ROE % only.
LGND' s ROE % Range Over the Past 10 Years
Min: -1046.55  Med: 30.84 Max: 997.71
Current: -0.48
-1046.55
997.71
ROA % -0.28
LGND's ROA % is ranked higher than
72% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. LGND: -0.28 )
Ranked among companies with meaningful ROA % only.
LGND' s ROA % Range Over the Past 10 Years
Min: -56.92  Med: 3.17 Max: 112.83
Current: -0.28
-56.92
112.83
ROC (Joel Greenblatt) % 758.43
LGND's ROC (Joel Greenblatt) % is ranked higher than
97% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. LGND: 758.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LGND' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1252.88  Med: -29.29 Max: 6370.4
Current: 758.43
-1252.88
6370.4
3-Year Revenue Growth Rate 30.40
LGND's 3-Year Revenue Growth Rate is ranked higher than
80% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. LGND: 30.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LGND' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -65  Med: 9.9 Max: 91
Current: 30.4
-65
91
3-Year EBITDA Growth Rate 45.60
LGND's 3-Year EBITDA Growth Rate is ranked higher than
88% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. LGND: 45.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LGND' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -76.7  Med: -13.9 Max: 112.5
Current: 45.6
-76.7
112.5
GuruFocus has detected 3 Warning Signs with Ligand Pharmaceuticals Inc $LGND.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LGND's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

LGND Guru Trades in Q1 2016

Joel Greenblatt 21,822 sh (New)
Columbia Wanger 158,034 sh (New)
Paul Tudor Jones 3,900 sh (+58.02%)
Ken Fisher 70,583 sh (unchged)
RS Investment Management 912,545 sh (-16.26%)
Jim Simons 116,800 sh (-32.99%)
» More
Q2 2016

LGND Guru Trades in Q2 2016

Joel Greenblatt 71,870 sh (+229.35%)
Columbia Wanger 202,341 sh (+28.04%)
Paul Tudor Jones 4,400 sh (+12.82%)
Ken Fisher 72,390 sh (+2.56%)
Jim Simons 116,004 sh (-0.68%)
RS Investment Management 824,750 sh (-9.62%)
» More
Q3 2016

LGND Guru Trades in Q3 2016

Ken Fisher 72,390 sh (unchged)
Jim Simons Sold Out
Columbia Wanger 123,594 sh (-38.92%)
Joel Greenblatt 38,231 sh (-46.81%)
Paul Tudor Jones 2,300 sh (-47.73%)
» More
Q4 2016

LGND Guru Trades in Q4 2016

Paul Tudor Jones Sold Out
Ken Fisher 65,490 sh (-9.53%)
Joel Greenblatt 33,965 sh (-11.16%)
Columbia Wanger 88,597 sh (-28.32%)
» More
» Details

Insider Trades

Latest Guru Trades with LGND

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:NKTR, NAS:AGIO, OTCPK:ABCZF, NAS:ONCE, NAS:SAGE, NYSE:CBM, NAS:ARRY, NAS:SRPT, NAS:LXRX, NAS:CLVS, NAS:HALO, OTCPK:BTGGF, OTCPK:MPSYY, NAS:FPRX, OTCPK:BVNRY, NAS:INVA, NAS:ICPT, NAS:CBPO, NYSE:EBS, NAS:ACOR » details
Traded in other countries:LGDN.Germany,
Ligand Pharmaceuticals Inc is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.

Ligand Pharmaceuticals Inc was incorporated in Delaware in 1987. It is a biopharmaceutical company engaged in developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. The Company has evaluated ASC 280 and has identified two reportable segments: the development and commercialization of drugs using Captisol technology by CyDex Pharmaceuticals, Inc. and the biopharmaceutical company. With its portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, the Company offers investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. It has multiple partnered programs in its portfolio that are either in or nearing the regulatory approval process. GSKs Promacta (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP. The Company currently receives royalty revenues from Pfizer, Inc., or Pfizer, for sales of the pain therapeutic Avinza. The drug is also marketed in Spain under the brand name Conbriza through a co-promotion with Almirall, an international pharmaceutical company based in Spain. The Company currently has no manufacturing facilities. It currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a supplier of active pharmaceutical ingredients, or APIs and API intermediates located in Portugal. Its competitive position also depends upon its ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the often substantial period between technological conception and commercial sales. The Company is subject to rigorous regulation by federal and various state authorities, including the FDA.

Ratios

vs
industry
vs
history
Forward PE Ratio 49.75
LGND's Forward PE Ratio is ranked lower than
53% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. LGND: 49.75 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 6.44
LGND's PB Ratio is ranked lower than
70% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. LGND: 6.44 )
Ranked among companies with meaningful PB Ratio only.
LGND' s PB Ratio Range Over the Past 10 Years
Min: 5.26  Med: 20.24 Max: 174.72
Current: 6.44
5.26
174.72
PS Ratio 20.87
LGND's PS Ratio is ranked lower than
68% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. LGND: 20.87 )
Ranked among companies with meaningful PS Ratio only.
LGND' s PS Ratio Range Over the Past 10 Years
Min: 4.63  Med: 19.21 Max: 714.32
Current: 20.87
4.63
714.32
Price-to-Free-Cash-Flow 109.26
LGND's Price-to-Free-Cash-Flow is ranked lower than
87% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 23.86 vs. LGND: 109.26 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LGND' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 42.12  Med: 73.18 Max: 302.12
Current: 109.26
42.12
302.12
Price-to-Operating-Cash-Flow 55.53
LGND's Price-to-Operating-Cash-Flow is ranked lower than
77% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 22.05 vs. LGND: 55.53 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LGND' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 36.05  Med: 60.04 Max: 3131.43
Current: 55.53
36.05
3131.43
EV-to-EBIT 51.67
LGND's EV-to-EBIT is ranked lower than
79% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 18.89 vs. LGND: 51.67 )
Ranked among companies with meaningful EV-to-EBIT only.
LGND' s EV-to-EBIT Range Over the Past 10 Years
Min: -933.3  Med: -3.95 Max: 548.4
Current: 51.67
-933.3
548.4
EV-to-EBITDA 41.29
LGND's EV-to-EBITDA is ranked lower than
75% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 16.23 vs. LGND: 41.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
LGND' s EV-to-EBITDA Range Over the Past 10 Years
Min: -227.8  Med: -3.2 Max: 823.2
Current: 41.29
-227.8
823.2
Shiller PE Ratio 41.70
LGND's Shiller PE Ratio is ranked higher than
62% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.81 vs. LGND: 41.70 )
Ranked among companies with meaningful Shiller PE Ratio only.
LGND' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.55  Med: 58.23 Max: 384.6
Current: 41.7
23.55
384.6
Current Ratio 0.72
LGND's Current Ratio is ranked lower than
90% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. LGND: 0.72 )
Ranked among companies with meaningful Current Ratio only.
LGND' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.32 Max: 8.13
Current: 0.72
0.57
8.13
Quick Ratio 0.71
LGND's Quick Ratio is ranked lower than
86% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. LGND: 0.71 )
Ranked among companies with meaningful Quick Ratio only.
LGND' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 1.32 Max: 8.12
Current: 0.71
0.53
8.12
Days Inventory 172.58
LGND's Days Inventory is ranked lower than
65% of the 314 Companies
in the Global Biotechnology industry.

( Industry Median: 129.42 vs. LGND: 172.58 )
Ranked among companies with meaningful Days Inventory only.
LGND' s Days Inventory Range Over the Past 10 Years
Min: 33.18  Med: 79.07 Max: 172.58
Current: 172.58
33.18
172.58
Days Sales Outstanding 49.24
LGND's Days Sales Outstanding is ranked higher than
61% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. LGND: 49.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
LGND' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.79  Med: 49.24 Max: 146.43
Current: 49.24
5.79
146.43
Days Payable 180.67
LGND's Days Payable is ranked higher than
84% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 56.51 vs. LGND: 180.67 )
Ranked among companies with meaningful Days Payable only.
LGND' s Days Payable Range Over the Past 10 Years
Min: 180.67  Med: 307.55 Max: 822.72
Current: 180.67
180.67
822.72

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.70
LGND's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. LGND: -0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LGND' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.8  Med: -7.3 Max: 0.3
Current: -0.7
-13.8
0.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 56.76
LGND's Price-to-Tangible-Book is ranked lower than
97% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. LGND: 56.76 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LGND' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 12.86  Med: 15.64 Max: 206.67
Current: 56.76
12.86
206.67
Price-to-Intrinsic-Value-Projected-FCF 4.30
LGND's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
57% of the 156 Companies
in the Global Biotechnology industry.

( Industry Median: 3.03 vs. LGND: 4.30 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LGND' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.16  Med: 5.91 Max: 7.65
Current: 4.3
4.16
7.65
Price-to-Median-PS-Value 1.09
LGND's Price-to-Median-PS-Value is ranked lower than
53% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. LGND: 1.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LGND' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 0.74 Max: 11.08
Current: 1.09
0.26
11.08
Earnings Yield (Greenblatt) % 1.94
LGND's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. LGND: 1.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LGND' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 1.3 Max: 2
Current: 1.94
0.2
2

More Statistics

Revenue (TTM) (Mil) $109.0
EPS (TTM) $ -0.10
Beta1.22
Short Percentage of Float26.00%
52-Week Range $87.50 - 139.79
Shares Outstanding (Mil)20.90

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 140 186 230
EPS ($) 2.55 3.83 4.94
EPS without NRI ($) 2.55 3.83 4.94
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for LGND

Headlines

Articles On GuruFocus.com
Gurus Invest in Top Biotechnology Stocks Jun 20 2016 
RS Investment Increases Holdings in Ulta Salon, Noble Energy and Fortune Brands Dec 23 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 

More From Other Websites
Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: 2016 By the Numbers : March 1, 2017 Mar 01 2017
Ligand Provides Highlights from Today’s Analyst Day Event Feb 28 2017
4:04 pm Ligand Pharma expands its license with Sermonix Pharmaceuticals to include worldwide rights... Feb 28 2017
Ligand Expands License with Sermonix to Include Worldwide Rights for Oral Lasofoxifene Feb 28 2017
6 Stocks on the Move With Unusual Volume Feb 28 2017
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 28 2017
Sermonix Pharmaceuticals Secures Worldwide Rights to Oral Lasofoxifene From Ligand Pharmaceuticals,... Feb 28 2017
LIGAND PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 28 2017
Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q4, 2016 By the Numbers : February 27,... Feb 27 2017
Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes Feb 27 2017
Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates Feb 24 2017
Edited Transcript of LGND earnings conference call or presentation 23-Feb-17 9:30pm GMT Feb 24 2017
Ligand reports 4Q loss Feb 23 2017
Ligand reports 4Q loss Feb 23 2017
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Feb 23 2017
Ligand Reports Fourth Quarter and Full Year 2016 Financial Results Feb 23 2017
Q4 2016 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open Feb 23 2017
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More Feb 22 2017
Forget Alexion, Buy these 4 Biotech Stocks Instead Feb 20 2017
Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US :... Feb 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)